Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information


What is Captisol®?

Captisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to maximize safety and optimize interaction to improve the solubility, stability and administration of active ingredients.

Ligand offers formulation solutions, in-depth industry knowledge and consulting services to meet your goals. Ligand has strong Captisol®-related alliances with partners to deliver enabling solutions to products.


Captisol® is a well profiled enabling technology available to research and development professionals through flexible licensing arrangements. We work worldwide with companies interested in licensing Captisol® and other SBE-CD technologies to commercialize their products. We also work with our partners to manage life cycles of existing products. 

  • Pharmaceutical Product Development services
  • Commercial License and Supply Agreement (LSA)
  • Limited Clinical Use Agreements (LCUAs)

 Contact our Licensing Department

How to Use Captisol®

View our easy-to-use PDF for more information on how to use Captisol®

Download PDF

Interested In Partnering?

Contact us today and take the first step to a great partnership.

Contact Us